3 results
Primary Safety Objective * Proportion of patients who complete 24 weeks of combination treatment on pirfenidone at a dose of 1602*2403 mg/d and nintedanib at a dose of 200*300 mg/d Secondary Safety Objective * Proportion of patients who discontinue…
Study AimsPrimary Aim: This is a proof-of-concept study to evaluate the effect of ARA 290 in pain of patients with CRPS1 by means of once daily subcutaneous injection with ARA 290 for 4 weeks. Secondary Aims: * Assess the predictive effect of…
The main purpose of this pilot study is to assess the feasibility and potential efficacy of implant retained mandibular advancement device (MAD) therapy on a small scale in edentulous patients with mild to moderate OSA in terms of sleep apnea…